Get the Stockscreener App
4.70
2.08%
-0.10
After Hours:
4.84
0.14
+2.98%
Relay Therapeutics Inc stock is traded at $4.70, with a volume of 2.24M.
It is down -2.08% in the last 24 hours and down -20.34% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$4.80
Open:
$4.8
24h Volume:
2.24M
Relative Volume:
1.05
Market Cap:
$786.70M
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-1.7472
EPS:
-2.69
Net Cash Flow:
$-304.44M
1W Performance:
-1.05%
1M Performance:
-20.34%
6M Performance:
-24.07%
1Y Performance:
-41.69%
1-Day Range:
$4.665
$4.9299
1-Week Range:
$4.60
$5.03
52-Week Range:
$4.48
$12.14
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
399 BINNEY STREET, CAMBRIDGE
Compare RLAY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
4.70 | 786.70M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Braidwell LP Buys 492,628 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Eventide Asset Management LLC Buys New Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Acquired by Walleye Capital LLC - MarketBeat
Sio Capital Management LLC Acquires Shares of 945,839 Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Ally Bridge Group NY LLC Invests $4.43 Million in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
GSA Capital Partners LLP Sells 82,997 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics' SWOT analysis: oncology pioneer's stock faces pivotal phase - Investing.com
Layoff Tracker: Sonata Therapeutics Laying Off 20 Employees, Changing Leadership - BioSpace
Brokerages Set Relay Therapeutics, Inc. (NASDAQ:RLAY) Price Target at $21.22 - MarketBeat
Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround - Yahoo Finance
Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround - Yahoo Finance
First Turn Management LLC Buys New Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Trading Down 4.8% – Here’s What Happened - Defense World
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8%Time to Sell? - MarketBeat
Relay Therapeutics stock hits 52-week low at $5.59 - Investing.com India
(RLAY) Trading Report - Stock Traders Daily
Relay Therapeutics stock hits 52-week low at $5.59 By Investing.com - Investing.com UK
Analyzing Valneva (NASDAQ:VALN) and Relay Therapeutics (NASDAQ:RLAY) - Defense World
NKGen Biotech (NYSE:NKGN) versus Relay Therapeutics (NASDAQ:RLAY) Financial Contrast - Defense World
Relay Therapeutics' SWOT analysis: PI3K inhibitor progress fuels stock potential - Investing.com
HC Wainwright Forecasts Strong Price Appreciation for Relay Therapeutics (NASDAQ:RLAY) Stock - Defense World
Relay Therapeutics Gives Business Update - substack.com
Research Analysts Offer Predictions for RLAY FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for RLAY Issued By Leerink Partnrs - Defense World
Relay Therapeutics (NASDAQ:RLAY) Given New $20.00 Price Target at HC Wainwright - MarketBeat
Relay Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
RLAYRelay Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Relay Therapeutics Reports Q3 2024 Results and Advances - TipRanks
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights - The Manila Times
Relay Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Where are the Opportunities in (RLAY) - Stock Traders Daily
Relay Therapeutics (RLAY) to Release Earnings on Wednesday - MarketBeat
Relay Therapeutics stock hits 52-week low at $5.7 amid market shifts - Investing.com Australia
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 - The Manila Times
Relay Therapeutics stock hits 52-week low at $5.7 amid market shifts By Investing.com - Investing.com South Africa
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, - EIN News
Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapy - Barchart
Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses - Yahoo Finance
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Several Relay Therapeutics Insiders Sell Shares Sending Potential Negative Signal - Simply Wall St
Relay Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase - Investing.com Canada
Relay Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase By Investing.com - Investing.com South Africa
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):